### Aims and objectives of this session

Treatment options in metastatic patients are currently changing. More effective systemic therapies are available for prostate, bladder and kidney tumour patients. In this regard, the role of primary tumour surgery in the metastatic situation has to be discussed based on new clinical data. On the other hand, the impact of primary tumour on formation and therapy response of metastases has to be considered. In the first part of the session clinicians and researchers will present the current knowledge in this field and will also discuss the rationale of primary tumour surgery in metastatic patients. In the second part, challenges and prerequisites of immune checkpoint inhibition will be discussed including development of predictive markers.

### Scientific Programme - EAU19 Barcelona

**Current aspects of advanced tumour therapy: From bedside to bench**

Joint meeting of the EAU Section of Uropathology (ESUP) and the EAU Section of Urological Research (ESUR)

**Saturday 16 March**

10:15 - 14:00

**Location:** Green Area, Room 4

**Chairs:** K. Junker, Homburg (DE)  
R. Montironi, Ancona (IT)

#### 10:15 - 10:20

**Welcome and introduction**  
K. Junker, Homburg (DE)

#### 10:20 - 12:20

**The role of the primary tumour for metastatic disease**

*Moderators:*  
K. Junker, Homburg (DE)  
I. Heidegger, Innsbruck (AT)  
R. Montironi, Ancona (IT)

**10:20 - 10:35**

*Cytoreductive primary tumour surgery in metastatic disease - Prostate cancer: In?*  
M. Stöckle, Homburg (DE)

**10:35 - 10:50**

*Cytoreductive primary tumour surgery in metastatic disease - Kidney cancer: Out?*  
A. Mejean, Paris (FR)

**10:50 - 11:05**

*Cytoreductive primary tumour surgery in metastatic disease - Bladder cancer: Never ever?*  
G.N. Thalmann, Bern (CH)

**11:05 - 11:25**

*Crosstalk between primary tumour and metastasis and the role of exosomes*  
K. Junker, Homburg (DE)

**11:25 - 11:45**

*Reasonability of inductive therapy in urologic metastatic patients*  
A. Necchi, Milan (IT)

**11:45 - 12:15**

*Panel discussion*

**12:15 - 12:20**

*Discussion*

**12:20 - 13:20**

*Checkpoint inhibitors: The best for all patients?*  
*Moderators:* M. Colecchia, Milan (IT)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20 - 12:35</td>
<td>Do we understand checkpoint inhibition?</td>
</tr>
<tr>
<td>12:35 - 12:40</td>
<td>Discussion</td>
</tr>
<tr>
<td>12:40 - 12:55</td>
<td>The intestinal microbiota determines the clinical efficacies of immune checkpoint blockers targeting PD-1/PD-L1</td>
</tr>
<tr>
<td>12:55 - 13:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>13:00 - 13:15</td>
<td>PD-1, PD-L1…: What are the best predictive markers? Standardisation of marker analysis</td>
</tr>
<tr>
<td>13:15 - 13:20</td>
<td>Discussion</td>
</tr>
<tr>
<td>13:25 - 13:50</td>
<td>A translational approach to prostate cancer</td>
</tr>
<tr>
<td>13:20 - 13:50</td>
<td>Chopin award session</td>
</tr>
<tr>
<td>13:20 - 13:25</td>
<td>Dominique Chopin award</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>

Note: A. Lopez-Beltran, Lisbon (PT)  
A. Masson-Lecomte, Paris (FR)